FTC Settlement Targets Drug Costs: What It Means for You

Federal regulators have reached a significant settlement with Express Scripts, a major pharmacy benefit manager (PBM), aiming to curb artificially inflated drug prices. The Federal Trade Commission (FTC) alleged the company prioritized high-list-price drugs for larger rebates, increasing patient costs.

The new agreement prohibits Express Scripts from favoring higher-cost drugs solely for rebates. This is expected to save patients billions by ensuring access to more affordable medications. The settlement also mandates that out-of-pocket expenses be calculated based on a drug's net cost, not its inflated list price. For insulin users, a Patient Assurance Program will cap monthly costs at $25 for eligible products.

Express Scripts must also integrate TrumpRx, a direct-to-consumer pricing platform, into its standard offerings. This aims to provide patients access to negotiated cash prices that count towards deductibles. Furthermore, the company's Switzerland-based purchasing arm, Ascent Health Services, will be reshoring to the U.S. to enhance regulatory oversight.

Community pharmacies will benefit from a transparent payment formula based on actual drug acquisition costs plus a dispensing fee, addressing long-standing concerns about low reimbursement rates.

While this settlement targets Express Scripts, the FTC is pursuing similar actions against other PBMs, signaling potential widespread changes in the pharmaceutical pricing model.